Results 101 to 110 of about 626 (142)

Compatibility studies of Sodium oxybate oral solution

, 2019
Nātrija oksibutirāta orālā šķīduma savietojamības pētījumi. Valtere L. K., darba vadītāji Dr. ķīm., prof. Vīksna A., Mg. ķīm. Kuprevičs K., bakalaura darbs, 68 lappuses, 33 literatūras avoti, 4 pielikumi. Latviešu valodā. Darbā tika veikti savietojamības
Valtere, Līva Klinta
core  

Pharmacokinetics and formulation selection of FT218, an investigational controlledrelease sodium oxybate formulation designed for once nightly dosing

, 2019
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate is required to be taken twice nightly ...
Monteith, D, Roth, Thomas, Grassot, J, Castellan, C   +3 more
core  

Pharmacokinetics and dose proportionality of FT218, an investigational controlled release formulation of sodium oxybate for once nightly dosing

, 2019
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate, is required to be taken twice nightly ...
Monteith, D, Roth, Thomas, Grassot, J, Castellan, C   +3 more
core  

Treatment cost of narcolepsy with cataplexy in Central Europe

Therapeutics and Clinical Risk Management, 2016
Petra Maresova,1 Michal Novotny,2,3 Blanka Klímová,4 Kamil Kuča3,51Department of Economics, Faculty of Informatics and Management, 2Department of Chemistry, Faculty of Science, University of Hradec Králové, 3Biomedical ...
Maresova P, Novotny M, Klímová B, Kuča K   +3 more
doaj  

Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice

, 2015
The treatment of alcohol dependence (AD) with sodium oxybate (SMO) was introduced in Italy and Austria more than 20 years and 15 years ago respectively, and it is now widely employed.
Ceccanti, M, Domenicali, M, Bernardi, M, Caputo, F, Maremmani, I, Mirijello, A, Mosti, A, Cibin, M, Addolorato, G.   +8 more
core  

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary

Journal of Comparative Effectiveness Research
What is this summary about? This is a plain language summary of a published article in the journal Sleep. Narcolepsy is a sleep condition that has 2 different subtypes: narcolepsy type 1 and narcolepsy type 2. These are called NT1 and NT2 for short.
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Fèri Ascencion, Jennifer Gudeman   +6 more
doaj   +1 more source

Response to Letter to the Editor Regarding “Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients With Narcolepsy: A Commentary”

Neurology and Therapy
Chad Ruoff, Shawn Candler, Jed Black
doaj   +1 more source

Letter to the Editor regarding: “Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary” by R. Rosenberg et al

Neurology and Therapy
Thomas Roth
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium oxybate for narcolepsy

Expert Review of Neurotherapeutics, 2006
Sodium oxybate (Xyrem), also known as gamma-hydroxybutyric acid, is the only therapeutic specifically approved in the USA for the treatment of cataplexy in narcolepsy. The US FDA has recently expanded its indication to include excessive daytime sleepiness associated with narcolepsy.
openaire   +2 more sources

Sodium oxybate

Reactions Weekly, 2017
  +8 more sources